Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (754)	1/20/2000 5:23:00 PM
From: Dr. John M. de Castro	Read Replies (2) \| Respond to of 1494

There are some pretty good estimates of the ""s in the document. Harry Tracy (Neuroinvest) has indicated that the royalty split is: INDICATION MERZ NTI CCMC Merz Indication [92]% [8]% [*]% CMCC Indications [13]% [75]% [12]% That is why the results just announced for the neuropathic pain trial are so very important to NTII. They don't get a large share of Merz' dementia indication, although its a huge market and 8% of huge is significant. But, with Neuropathic Pain (NP) they get 75% of the revenue. There are no other available treatments for NP. The market is large. the patients have to take memantine every day so the revenues will be ongoing. Bottom line: memantine for NP has the potential to be a lucrative cash cow for NTII. The NP results just announced, IMHO are the turning point for NTII, and a fantastic birthday present for this correspondent. With these results the company's future goes from speculative to assured. We should see by summer, just how assured it will be. Best regards John de C